KMPHARMACEUTICAL Co.,Ltd.

225430KOSDAQChemicals and chemical products

KMPHARMACEUTICAL Co.,Ltd. (225430, KOSDAQ) reported KRW 16bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
2021231-15340Separate
202216-1-45136Separate
202318-1-15135Separate
202414-3-54933Separate
202516-3-44628Separate

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
20213.8%-2.7%75.8%-1.5%
2022-8%-25.1%70.8%-10.8%
2023-6.1%-7.4%70.2%-3.7%
2024-17.7%-31.6%66.6%-14%
2025-18.3%-24.8%60.9%-14%

Revenue moved -29.6% between 2021 and 2025.

Net profit was negative in the 5 most recent consecutive years on file. Counted from the 5 years in which the company filed a net-profit line — a year with no filing is skipped, not read as a loss.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 4bn
Close priceKRW 606
Listed shares6,485,675
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

When it was founded

The incorporation date on the company's registration record, as filed with Korea's Financial Supervisory Service. This is when the company was legally formed — not when it first listed, and not when the business it grew out of began trading.

Incorporated

Who runs it

Registered representative directors — in Korea this is the office a CEO holds. Filed with the Financial Supervisory Service (DART). A Korean company can register more than one, and the title beside each name is the rank they carry inside the company.

NameTitleBoard seatYears in post
Kang Il-mo (강일모)ChairmanInside director19 years
BAIK BRIAN SEUNG WON (백승원)PresidentInside director8 years

Roman spellings are ours, converted from the Korean filing. The person may spell their own name differently in English. The Korean name in brackets is what was filed.

Some Roman spellings here are not ours — the company filed them itself, either beside the Korean name or in place of one. Those are the spellings the company uses.

Workforce — a side measure, not the main one

Employees (2025)63
Women30 (47.6%)
Average tenure4.3 years
Annual pay, menKRW 50,727,273
Annual pay, womenKRW 34,000,000
Pay ratio, women to men67%

Other companies in Chemicals and chemical products

173 listed companies file under this classification. Showing 12.

See the whole Chemicals and chemical products list →